Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated price target is $140.00. Charlie CY Yang has ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

After hours: September 20 at 7:52 PM EDT Loading Chart for MRK ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Analysts see big upside for these undervalued health care stocks.

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...

According to tradition, a part of the Holy Cross was discovered by the mother of the emperor Constantine, St. Helen, on a pilgrimage to Jerusalem in 326. A fifth century account describes this ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...